NSAIDS: UNDERSTANDING COMMON AND UNCOMMON RISKS
CHRIS J. KOTTENSTETTE, PA-C, CPE
Past President, Colorado Academy of Physician Assistants
Clinical PA
Colorado Spine Institute, PLCC
Johnstown, CO
OTHER RECOMMENDED VIDEOS
ADVERTISEMENT
 |
THE CHANGING PAIN MANAGEMENT LANDSCAPE
JEFFREY GUDIN, MD
|
 |
TOPICAL ANALGESICS: THE IMPORTANCE OF FDA APPROVAL
STEVEN STANOS, DO
|
 |
APPROPRIATE PATIENTS FOR TOPICAL THERAPY: IMPORTANT CONSIDERATIONS
CHARLES ARGOFF, MD
|
 |
ACP AND AAFP GUIDELINE UPDATES FOR PAIN - WHERE DO TOPICALS FIT IN?
JEFFREY GUDIN, MD
|
 |
TOPICAL ANALGESICS: UNDERSTANDING THE MOA TO MAKE PROPER TREATMENT DECISIONS
STEVEN STANOS, DO
|
 |
PROPOSED NEW LOW-DOSE ASPIRIN GUIDELINES: A REVIEW OF ORAL NSAIDS
JEFFREY GUDIN, MD
|
 |
BEST PRACTICES IN PAIN MANAGEMENT
JEFFREY GUDIN, MD
|
 |
DIFFERENTIATING RISK BETWEEN ORAL AND TOPICAL MEDICATIONS- BACKED BY SCIENCE
JEFFREY GUDIN, MD
|
 |
TOPICAL ANALGESICS: CHOOSING THE PROPER MEDICATION
JEFFREY GUDIN, MD
|
 |
THE IMPORTANCE OF FDA APPROVAL OF TOPICAL MEDICATIONS
JEFFREY GUDIN, MD
|
 |
THE CHANGING PAIN MANAGEMENT LANDSCAPE
CHARLES ARGOFF, MD
|
 |
INCORPORATING TOPICAL THERAPIES AS PART OF A MULTI- MODAL TREATMENT APPROACH
CHARLES ARGOFF, MD
|
 |
USING EVIDENCE-BASED MEDICAL MANAGEMENT WHEN CHOOSING TOPICAL THERAPIES
CHARLES ARGOFF, MD
|
 |
ASSESSMENT AND DIAGNOSIS OF THE PAIN PATIENT: EVALUATING THE WHOLE PATIENT
STEVEN STANOS, DO
|
 |
RISK MITIGATION STRATEGIES: UNDERSTANDING INTERPATIENT VARIABILITY
STEVEN STANOS, DO
|
 |
ACP/ACR/AAFP GUIDELINE UPDATES: A PERSON CENTERED APPROACH TO CARE
STEVEN STANOS, DO
|
 |
Proposed Guideline Changes for Low-Dose Aspirin for Primary Prevention of Cardiovascular Disease (CVD)
Chris J. Kottenstette, PA-C, CPE
|
 |
NSAIDS: Understanding Common and Uncommon Risks
Chris J. Kottenstette, PA-C, CPE
|
 |
NSAIDS: Differentiating Oral vs. Topical
Chris J. Kottenstette, PA-C, CPE
|
 |
ACP/AAFP Guideline Updates for Musculoskeletal Pain
Chris J. Kottenstette, PA-C, CPE
|
 |
Safety and Efficacy of Over the Counter Products: The Importance of FDA Approval
Chris J. Kottenstette, PA-C, CPE
|
 |
Best Practices in Pain Management: Minimizing Risk through Rational Polypharmacy
Chris J. Kottenstette, PA-C, CPE
|
 |
The Changing Landscape in Pain Management
THERESA (TRACEY) MALLICK-SEARLE, MS, PMGT-BC, ANP-BC
|
 |
Topical Analgesics: Updates to Clinical Guidelines
THERESA (TRACEY) MALLICK-SEARLE, MS, PMGT-BC, ANP-BC
|
 |
NSAIDS: Risk Mitigation Strategies
THERESA (TRACEY) MALLICK-SEARLE, MS, PMGT-BC, ANP-BC
|
 |
OTC Topical Analgesics: Cutting Through the Noise
THERESA (TRACEY) MALLICK-SEARLE, MS, PMGT-BC, ANP-BC
|
 |
Best Practices in Pain Management for Frontline Clinicians
THERESA (TRACEY) MALLICK-SEARLE, MS, PMGT-BC, ANP-BC
|
 |
The Expanding Role of the NP/PA in Practice
THERESA (TRACEY) MALLICK-SEARLE, MS, PMGT-BC, ANP-BC
|
 |
Proper Patient Assessment, Diagnosis, and Treatment
JEREMY A. ADLER, DMSC, PA-C
|
 |
Treatment Decisions: Understanding the Rehabilitative Model vs. Palliative Model
JEREMY A. ADLER, DMSC, PA-C
|
 |
Patient Expectations and Goal Setting
JEREMY A. ADLER, DMSC, PA-C
|
 |
Topical Medications: Understanding Side Effects of Treatment
JEREMY A. ADLER, DMSC, PA-C
|
 |
Where do OTC Treatments Fit Into Practice?
JEREMY A. ADLER, DMSC, PA-C
|
 |
Future Opportunities in the Pain Management Field
JEREMY A. ADLER, DMSC, PA-C
|
 |
Importance of FDA Approval for Topical Therapies
JEREMY A. ADLER, DMSC, PA-C
|
ADVERTISEMENT